Core A (Administrative Core) will provide all the logistic, scientific, managerial, and financial oversight to facilitate and to coordinate the studies described in this IPCAVD program. Centralized administration is critical for efficient project management and coordination. The Administrative Core will ensure that the preclinical studies (Project 1), clinical studies (Project 2), and manufacturing program (Project 3) adhere to the timelines and deliverables described in those sections of this IPCAVD program. The Administrative Core will organize weekly conference calls and regular in-person meetings among the investigators, interface with HVTN clinical sites, maintain regulatory approvals for all preclinical and clinical studies, provide fiscal and logistic oversight, manage subcontracts, and coordinate meetings with the Scientific Advisory Committee and DAIDS Program Officials. This detailed administration and management structure will ensure that all the studies remain focused on the overall objective to advance the novel heterologous rAd prime-boost HIV-1 vaccine into phase 1 and phase 2a clinical trials. To accomplish these goals, we propose the following four Specific Aims: 1. To coordinate communications, interactions, and operations among investigators, projects, and collaborators to facilitate the overall progress and goals of this IPCAVD program; 2. To ensure and to maintain regulatory compliance for all preclinical and clinical studies; 3. To provide detailed financial oversight and management for projects and subcontracts;and 4. To coordinate meetings with the Scientific Advisory Committee and DAIDS Program Officials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-CCH-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Penaloza MacMaster, Pablo; Shields, Jennifer L; Alayo, Quazim A et al. (2017) Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. Vaccine 35:1-9
Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270
Provine, Nicholas M; Badamchi-Zadeh, Alexander; Bricault, Christine A et al. (2016) Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses. J Virol 90:4278-88
Stephenson, Kathryn E; Neubauer, George H; Bricault, Christine A et al. (2016) Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis 3:ofw100
Handley, Scott A; Desai, Chandni; Zhao, Guoyan et al. (2016) SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. Cell Host Microbe 19:323-35
Larocca, Rafael A; Provine, Nicholas M; Aid, Malika et al. (2016) Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+T cell responses that impair CD8+T cell function. Sci Immunol 1:
Provine, Nicholas M; Larocca, Rafael A; Aid, Malika et al. (2016) Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. J Immunol 197:1809-22
Tartaglia, Lawrence J; Chang, Hui-Wen; Lee, Benjamin C et al. (2016) Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences. PLoS Pathog 12:e1005431
Barouch, Dan H; Ghneim, Khader; Bosche, William J et al. (2016) Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. Cell 165:656-67
Gandhi, Rajesh T; Kwon, Douglas S; Macklin, Eric A et al. (2016) Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J Acquir Immune Defic Syndr 71:246-53

Showing the most recent 10 out of 87 publications